Antiretrovirals to prevent HIV infection: Pre- and postexposure prophylaxis

Current Infectious Disease Reports

Volumn 10, Issue 4, 2008, Pages 323-331

  Gay, Cynthia L ^a   Cohen, Myron S ^b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; MARAVIROC; PLACEBO; TENOFOVIR; ZIDOVUDINE;

ABNORMAL LABORATORY RESULT; ANTIVIRAL ACTIVITY; CD4 LYMPHOCYTE COUNT; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; NONHUMAN; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PATIENT CARE; PATIENT COUNSELING; POPULATION RISK; PRACTICE GUIDELINE; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEROCONVERSION; SEXUAL BEHAVIOR; SEXUAL TRANSMISSION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VIRUS DETECTION; VIRUS LOAD; VIRUS SHEDDING; VIRUS TRANSMISSION;

EID: 56349130250     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0052-5     Document Type: Review

References (79)

1. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000, 342:921-929.
2. Garcia PM, Kalish LA, Pitt J, et al.: Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999, 341:394-402.
3. Richardson BA, John-Stewart GC, Hughes JP, et al.: Breast-milk infectivity in human immunodeficiency virus type 1-infected mothers. J Infect Dis 2003, 187:736-740.
4. Fideli US, Allen SA, Musonda R, et al.: Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses 2001, 17:901-910.
5. Tovanabutra S, Robison V, Wongtrakul J, et al.: Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr 2002, 29:275-283.
6. Coombs RW, Reichelderfer PS, Landay AL: Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS 2003, 17:455-480.
7. Lampinen TM, Critchlow CW, Kuypers JM, et al.: Association of antiretroviral therapy with detection of HIV-1 RNA and DNA in the anorectal mucosa of homosexual men. AIDS 2000, 14:F69-F75.
8. Cohen MS, Hoffman IF, Royce RA, et al.: Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997, 349:1868-1873.
9. Ghys PD, Fransen K, Diallo MO, et al.: The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 1997, 11:F85-F93.
10. Pilcher CD, Joaki G, Hoffman IF, et al.: Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS 2007, 21:1723-1730.
11. Wawer MJ, Gray RH, Sewankambo NK, et al.: Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005, 191:1403-1409.
12. Brenner BG, Roger M, Routy JP, et al.: High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis 2007, 195:951-959.
13. Were WA, Mermin JH, Wamai N, et al.: Undiagnosed HIV infection and couple HIV discordance among household members of HIV-infected people receiving antiretroviral therapy in Uganda. J Acquir Immune Defic Syndr 2006, 43:91-95.
14. Musicco M, Lazzarin A, Nicolosi A, et al.: Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med 1994, 154:1971-1976.
15. Castilla J, Del Romero J, Hernando V, et al.: Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr 2005, 40:96-101.
16. Kayitenkore K, Bekan B, Rufagari J, et al.: The impact of ART on HIV transmission among HIV serodiscordant couples. Presented at the XVI International AIDS Conference. Toronto, Canada; August 13-16, 2006.
17. Bunnell R, Ekwaru JP, Solberg P, et al.: Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006, 20:85-92.
18. Porco TC, Martin JN, Page-Shafer KA, et al.: Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS 2004, 18:81-88.
19. Fang CT, Hsu HM, Twu SJ, et al.: Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis 2004, 190:879-885.
20. Katz MH, Schwarcz SK, Kellogg TA, et al.: Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health 2002, 92:388-394.
21. Dukers NH, Spaargaren J, Geskus RB, et al.: HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS 2002, 16:F19-F24.
22. Cohen MS, Gay C, Kashuba AD, et al.: Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med 2007, 146:591-601.
23. Garcia-Lerma JG, Otten RA, Qari SH, et al.: Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 2008, 5:e28.
24. Subbarao S, Ramos A, Kim C, et al.: Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention. J Med Primatol 2007, 36:238-243
25. Sun Z, Denton PW, Estes JD, et al.: Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med 2007, 204:705-714.
26. Denton PW, Estes JD, Sun Z, et al.: Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 2008, 5:e16.
27. Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997, 337:1485-1490.
28. Panlilio AL, Cardo DM, Grohskopf LA, et al.: Updated US Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 2005, 54(RR-9):1-17.
29. Martin NV, Almeda J, Casabona J: Effectiveness and safety of HIV post-exposure prophylaxis after sexual, injecting-drug-use or other non-occupational exposure [protocol]. Cochrane Database of Systematic Reviews 2005, 2:CD005273.
30. Smith DK, Grohskopf LA, Black RJ, et al.: Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep 2005, 54(RR-2):1-20.
31. Roland ME, Neilands TB, Krone MR, et al.: Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005, 41:1507-1513.
32. Kindrick A, Tang H, Sterkenberg C, et al.: HIV post-exposure prophylaxis following sexual exposure is started too late for optimal benefit. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
33. Poynten IM, Smith DE, Cooper DA, et al.: The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Med 2007, 8:374-381.
34. Quirino T, Niero F, Ricci E, et al.: HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients. Antivir Ther 2000, 5:195-197.
35. Bassett IV, Freedberg KA, Walensky RP: Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis 2004, 39:395-401.
36. Ippolito G, Puro V: Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis. Am J Med 1997, 102:58-62.
37. Wang SA, Panlilio AL, Doi PA, et al.: Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol 2000, 21:780-785.
38. Puro V, De Carli G, Orchi N, et al.: Short-term adverse effects from and discontinuation of antiretroviral post-exposure prophylaxis. J Biol Regul Homeost Agents 2001, 15:238-242.
39. Sonder GJ, van den Hoek A, et al.: Trends in HIV postexposure prophylaxis prescription and compliance after sexual exposure in Amsterdam, 2000-2004. Sex Transm Dis 2007, 34:288-293.
40. Mayer KH, Mimiaga MJ, Cohen D, et al.: Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston community health center. J Acquir Immune Defic Syndr 2008, 47:494-499.
41. Kahn JO, Martin JN, Roland ME, et al.: Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study. J Infect Dis 2001, 183:707-714.
42. Winston A, McAllister J, Amin J, et al.: The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis. HIV Med 2005, 6:191-197.
43. Wiebe ER, Comay SE, McGregor M, Ducceschi S: Offering HIV prophylaxis to people who have been sexually assaulted: 16 months' experience in a sexual assault service. CMAJ 2000, 162:641-645.
44. Vernazza PL, Troiani L, Flepp MJ, et al.: Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS 2000, 14:117-121.
45. Cu-Uvin S, Snyder B, Harwell JI, et al.: Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr 2006, 42:584-587.
46. Kotler DP, Shimada T, Snow G, et al.: Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis. AIDS 1998, 12:597-604.
47. Graham SM, Holte SE, Peshu NM, et al.: Initiation of antiretroviral therapy leads to a rapid decline in cervical and vaginal HIV-1 shedding. AIDS 2007, 21:501-507.
48. Reddy S, Troiani L, Kim J, et al.: Differential phosphorylation of zidovudine and lamivudine between semen and blood mononuclear cells in HIV-1 infected men. Presented at the 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 10-14, 2003.
49. Dumond JB, Yeh RF, Patterson KB, et al.: Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS 2007, 21:1899-1907.
50. Vourvahis M, Tappouni HL, Patterson KB, et al.: The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr 2008, 47:329-333.
51. Dumond J, Patterson K, Pecha A, et al.: Marayiroc (MRV) genital tract (GT) fluid and tissue pharmacokinetics (PK) in healthy female volunteers: implications for pre- or post-exposure prophylaxis (PrEP or PEP). Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 3-6, 2008.
52. Vourvahis M, Tappouni H, Patterson K, et al.: A pharmacologic basis for the use of tenofovir in pre- and post-exposure prophylaxis: intra and extracellular genital tract pharmacokinetics and pharmacodynamics from first dose to steady state in HIV-1 infected men and women [abstract 569]. Presented at the 13th Annual Conference on Retroviruses and Opportunistic Infections, Denver, CO; February 5-8, 2006.
53. Lederman MM, Veazey RS, Offord R, et al.: Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004, 306:485-487.
54. Van Rompay KK, Schmidt KA, Lawson JR, et al.: Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus. J Infect Dis 2002, 186:1508-1513.
55. Subbarao S, Otten RA, Ramos A, et al.: Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006, 194:904-911.
56. Garcia-Lerma J, Otten R, Qari S, et al.: Prevention of rectal SHIV transmission in macaques by tenofovir/FTC combination. Presented at the 13th Annual Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5-8, 2006.
57. Magierowska M, Bernardin F, Garg S, et al.: Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques. J Virol 2004, 78:2434-2444.
58. Smith D, Kebaabetswe P, Disasi K, et al.: Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modelling approach. Presented at the XVI International AIDS Conference. Toronto, Canada; August 13-18, 2006.
59. Bill and Melinda Gates Foundation: Family health international receives grant to evaluate once-daily antiretroviral as a potential method of HIV prevention [press release]. Available at http://www.gatesfoundation.org/GlobalHealth/Pri_Diseases/HIVAIDS/ Announcements/Announce-021028.htm. Accessed May 5, 2008.
60. Centers for Disease Control and Prevention: CDC trials of pre-exposure prophylaxis for HIV prevention. Available at http://www.cdc.gov/hiv/resources/factsheets/prep.htm. Accessed May 5, 2008.
61. AIDS Vaccine Advocacy Coalition: PrEP watch. Available at http://www.prepwatch.org/index.htm. Accessed May 8, 2007.
62. Peterson L, Taylor D, Roddy R, et al.: Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials 2007, 2:e27.
63. Costello D: AIDS pill as party drug? Los Angeles Times. December 19, 2005:F1.
64. Cohen J: Protect or disinhibit? New York Times. January 22, 2006:12.
65. Kellerman SE, Hutchinson AB, Begley EB, et al.: Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr 2006, 43:376-377.
66. Mayer KH, Maslankowski L, Gai F, et al.: Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006, 20:543-551.
67. Schwartz J, Kashuba A, Rezk N, et al.: Preliminary results from a pharmacokinetic study of the candidate vaginal microbicide agent 1% tenofovir gel. Presented at Microbicides 2008. New Delhi, India; February 24-27, 2008.
68. Blower SM, Gershengorn HB, Grant RM: A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000, 287:650-654.
69. Law MG, Prestage G, Grulich A, et al.: Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001, 15:1287-1294.
70. Velasco-Hernandez JX, Gershengorn HB, Blower SM: Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2002, 2:487-493.
71. Abbas UL, Anderson RM, Mellors JW: Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE 2007, 2:e875.
72. Shoptaw S, Rotheram-Fuller E, Landovitz RJ, et al.: Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention. AIDS Care 2007:1-6.
73. Grulich A, Jin FY, Prestage G, et al.: Previous use of non-occupational post exposure prophylaxis against HIV (NPEP) and subsequent HIV infection in homosexual men: data from the HIM cohort. Presented at the XVI International AIDS Conference. Toronto, Canada; August 13-18, 2006.
74. Golub SA, Rosenthal L, Cohen DE, Mayer KH: Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection. AIDS Behav 2007
75. Martin JN, Roland ME, Torsten BN, et al.: Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS 2004, 18:787-792.
76. Kalichman SC: Post-exposure prophylaxis for HIV infection in gay and bisexual men. Implications for the future of HIV prevention. Am J Prev Med 1998, 15:120-127.
77. Pilcher CD, Price MA, Hoffman IF, et al.: Frequent detection of acute primary HIV infection in men in Malawi. AIDS 2004, 18:517-524.
78. Fiscus SA, Pilcher CD, Miller WC, et al.: Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis 2007, 195:416-424.
79. Bjorn G: Swiss stance on HIV transmission sparks concern. Nat Med 2008, 14:227.